biostudies-literatureSteber CRNCATS NIH HHSNCINCI NIH HHS152-156https://www.ebi.ac.uk/biostudies/studies/S-EPMC8559790biostudies-literatureUnknown111(1)<h4>Purpose</h4>Long-term outcomes after external beam radiation therapy (EBRT) and radiofrequency ablation (RFA) for medically inoperable early-stage non-small cell lung cancer (NSCLC) are not well known.<h4>Methods and materials</h4>Patients with medically inoperable early-stage NSCLC were enrolled in a prospective single-arm, phase 2 study between June 2007 and October 2008 and were treated with RFA followed by EBRT. Radiation was delivered using hypofractionated radiation therapy (HFRT; 70.2 Gy in 26 fractions) or stereotactic body radiation therapy (54 Gy in 3 fractions).<h4>Results</h4>Twelve patients were evaluable; 10 patients were treated with HFRT. The cumulative incidence of local progression at 5 years was 16.7% (95% confidence interval [CI], 0-37.8). Median progression-free suInternational journal of radiation oncology, biology, physicsLong-Term Outcomes From a Phase 2 Trial of Radiofrequency Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer.PMC8559790P30 CA012197KL2 TR001421Hughes RTUrbanic JClark HPetty WJBlackstock AWSteber CRFarris MKfalseLong-Term Outcomes From a Phase 2 Trial of Radiofrequency Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer.<h4>Purpose</h4>Long-term outcomes after external beam radiation therapy (EBRT) and radiofrequency ablation (RFA) for medically inoperable early-stage non-small cell lung cancer (NSCLC) are not well known.<h4>Methods and materials</h4>Patients with medically inoperable early-stage NSCLC were enrolled in a prospective single-arm, phase 2 study between June 2007 and October 2008 and were treated with RFA followed by EBRT. Radiation was delivered using hypofractionated radiation therapy (HFRT; 70.2 Gy in 26 fractions) or stereotactic body radiation therapy (54 Gy in 3 fractions).<h4>Results</h4>Twelve patients were evaluable; 10 patients were treated with HFRT. The cumulative incidence of local progression at 5 years was 16.7% (95% confidence interval [CI], 0-37.8). Median progression-free su2021-01-01T00:00:00Z2021 Sep2025-04-18T18:43:19.382Z2025-04-07T06:24:42.55ZS-EPMC85597903393253110.1016/j.ijrobp.2021.04.020